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Abstract: The mean percentage of cryptogenic strokes among ischemic strokes is 31%, of which one-third may be associ-
ated with patent foramen ovale. The foramen ovale is required for blood flow through the fetal atrial septum. It
is formed as of the fourth week of gestation, and this leads to right-left interatrial shunt that allows the passage
of oxygenated blood to systemic circulation. In 75% of cases, its closure is complete by 2 years of age, but it may
persist in 25% of patients. We present the case of a patient with paradoxical embolism in the lower extremities
and ischemic stroke in the clinical context of a patent foramen ovale.
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1. Introduction
The mean percentage of cryptogenic strokes among ischemic
strokes is 31%, of which one-third may be associated with
patent foramen ovale (1). The foramen ovale is required for
blood flow through the fetal atrial septum. It is formed as of
the fourth week of gestation, and this leads to right-left in-
teratrial shunt that allows the passage of oxygenated blood
to systemic circulation. In 75% of cases, its closure is com-
plete by 2 years of age, but it may persist in 25% of patients
(2). Here a rare presentation of embolism was reported as an
excuse to discuss a special aspect of paradoxical thromboem-
bolism.
2. Case presentation:
A 64-year-old female patient was admitted to emergency
department due to sudden asthenia, adynamia, vertiginous
sensation, and feeling faint. Subsequently, she reports
retrosternal chest pain that was associated with dyspnea,
dysarthria, bradypsychia, and hypoprosexia. Therefore, the
immediate response team goes into action for stroke code
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activation. Medical history of importance was that she un-
derwent left knee arthroscopy three days before admission.
Her vital signs on arrival were as follows: blood pressure,
90/60 mmHg; heart rate 59 beats/minute; respiratory rate,
18 breaths/minute; and axillary temperature, 36.9 ◦C. From
a neurological point of view, she was alert, disoriented in
time with fluctuating nomination, repetition alteration, pho-
netic, semantic paraphasias, and hypoesthesia in right side
of body. Brain magnetic resonance imaging (MRI) and mag-
netic resonance angiography (MRA) shows small acute in-
farctions at the left frontal cortical, probably due to hypo-
perfusion or micro emboli (Figure 1). Afterwards, a trans-
esophageal echocardiogram was carried out, which shows a
foramen ovale that allows passage of abundant amount of
bubbles to the left atrium, associated with severe tricuspid
valve insufficiency and high probability of pulmonary hyper-
tension (pulmonary artery systolic pressure of 58 mmHg).
Due to the findings from the echocardiogram, a ventricu-
lar B-type Natriuretic Peptide (BNP) test was conducted with
a result of 132 pg/ml, as well as high sensitivity troponin I
assay with a result of 1044 ng/dl (reference value 50 ng/dl).
The pretest probability was calculated using the Wells’ scale
and a high probability was obtained. Therefore, a com-
puted tomography (CT) angiography was carried out, and
it showed evidence of pulmonary thromboembolism which
jeopardizes the segmental and sub-segmental branches of
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Figure 1: Brain magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) of patient.
Figure 2: Axial and coronal plan cuts of chest angiogram.
the upper lobes, lingula, middle lobe, and both lower lobes
(Figure 2). The risk of paradoxical embolism (RoPE) score
was calculated, and it shows an intermediate probability. The
pulmonary embolism severity index (PESI) score was deter-
mined to be 154 points that corresponds to a class V risk (very
high risk). From the above findings, paradoxical embolism
has manifested itself due to vascular ischemic attack and pul-
monary embolism of intermediate risk as a result of elevated
troponin levels and signs of right ventricular dysfunction, in
the context of a patent foramen ovale. Full anticoagulation
treatment was started with heparins of low molecular weight,
enoxaparin, and the patient is considered not to be a suit-
able candidate for thrombolysis with instructions to be mon-
itored in an intensive care unit (ICU). The patient satisfacto-
rily evolved and in view of clinical improvement, the patient
is discharged with the Factor Xa inhibitor (Apixaban) without
a loading dose. Treatment was continued for 6 months, in
addition to physical rehabilitation and language therapy. An
outpatient control was held a month after the event, and ma-
jor neurological improvement was evidenced but paraphasia
is still present.
3. Discussion:
Although the majority of people with patent foramen ovale
are asymptomatic, this can become a transit channel for ve-
nous/arterial emboli, also known as paradoxical embolism.
It can lead to a variety of clinical conditions such as stroke
with an increase of twice the risk of death and disability in the
long term (3). Paradoxical embolism is defined as the passage
of a thrombus from the venous circulatory system to the sys-
temic circulation. For it to occur, specific clinical conditions,
such as the following, must be fulfilled (4):
1. In the majority of cases, it is associated with the presence
of risk factors that increase the likelihood of occurrence such
as hypercoagulable states, recent post-operation states, be-
ing bedridden for prolonged periods, and having a history of
neoplastic diseases of malignant etiology.
2. An anatomical communication between the venous sys-
tem and the systemic circulation is required, as well as patent
foramen ovale or defects in the septum at the atrial septum
level.
3. Lastly, it is conditioned by an increase of the pressure
gradient from right to left, as are Valsalva maneuvers. For
a proper definition, paradoxical embolism is the incidental
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manifestation of a venous thrombosis with a pulmonary em-
bolism associated with a systemic embolism; which clini-
cally presents itself in the vast majority of cases as an is-
chemic cerebrovascular event that may be acute or transi-
tory. The patent foramen ovale can be found in about 30%
of patients with ischemic cerebrovascular disease as an only
finding (1). Its prevalence appears to decrease with an in-
crease in age, with an incidence of 34% during the first 3
decades of life, 25% between the third and seventh decade,
and less than 20% in the octogenarian stage (5). The risk of
paradoxical embolism was revised in the RoPE Study which
marks a large collaborative effort to pool research on cryp-
togenic stroke and patent foramen ovale. Outcome events
have been adjudicated so that recurrent stroke can be mod-
eled excluding those with a non-patent foramen ovale related
mechanism (6). The treatment for secondary prevention is
unknown. Antiplatelet therapy and oral anticoagulants in
single or combined therapy can be used. Warfarin aspirin
recurrent stroke study (WARSS) with a population of 2206,
was a double-blind randomized multicenter study that com-
pared acetylsalicylic acid with warfarin in the prevention of
ischemic cerebrovascular event. Regardless of the presence
of patent foramen ovale, there was no significant difference
between warfarin and acetylsalicylic acid (7). Patent foramen
ovale in cryptogenic stroke study (PICCS), another random-
ized multi-centered study evaluated 630 patients to compare
warfarin (INR 1.4 - 2.8) and acetylsalicylic acid (325mg/mg)
in patients with patent foramen ovale and stroke. It was
noted that there is no significant difference between the two
treatment strategies. However, the absolute risk for death
or ischemic stroke was reduced by approximately half with
the use of warfarin compared with acetylsalicylic acid in the
subgroup of patent foramen ovale (8). In both studies, there
was more presence of minor bleeding in the vitamin K an-
tagonist group. In our specific case, oral anticoagulants are
the first measure given that the need for thrombolysis in pa-
tients with acute pulmonary embolism without hypotension
nor shock, places it as an intermediate-low risk and would
only be implemented in a selected population. However,
as of this moment, tracers that help define which patients
will benefit from thrombolysis do not exist. Individual trac-
ers of right ventricular dysfunction and myocardial injury
have an insufficient positive predictive value for complica-
tions and decision-making with regard to this therapy (9).
The pulmonary embolism thrombolysis (PEITHO) study de-
termined the effectiveness and safety of early thrombolytic
therapy in normotensive patients with right ventricular dys-
function, detected in an echocardiographic scan or through
a computerized axial tomography, or evidence of cardiac is-
chemic injury through proof of positive troponin (10). How-
ever, this study showed that the thrombolytic therapy pre-
vented the hemodynamic decompensation in the future, and
increases the risk of severe bleeding and hemorrhagic cere-
brovascular disease. Which in the clinical context of our
patient was highly probable due to the presence of recent
ischemic cerebrovascular disease and the prior orthopedic
surgery. With these findings, the next step was to determine
the risk stratification in subgroups to know if they benefited
from the early recanalization therapy through the adminis-
tration of fibrinolytic treatment. The study conducted by
Bova et al. demonstrated that three stages (I, II, III) were
identified through the calculation of a seven-point risk in-
dex, which showed rates of complications related with pul-
monary embolism after 30 days at 4.2%, 10.8% and 29.2%,
respectively (11). Again, the risk in our patient was raised,
calculating a stage III Bova index, which in view of the pre-
sented evidence, defined the need of our patient to undergo
thrombolytic therapy to prevent complications and mortality
in the next 30 days. However, this would be applicable to pa-
tients with only thrombus pulmonary embolism and there is
no solid evidence in patients with paradoxical embolism and
much less in ischemic stroke. Therefore, for future studies, it
is necessary to validate this data and issue suggestions with
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